1. AstraZeneca and Bristol-Myers Squibb

Who: AstraZeneca 
With: Bristol-Myers Squibb
What: $1.05 billion collaboration

Summary: In an unusual partnership between drug giants, AstraZeneca agreed to pay Bristol-Myers Squibb $100 million up front and up to $950 million more in milestones to partner up on two new drugs for the hot diabetes market. AstraZeneca has also agreed to take on 75 percent of the development costs of both late-stage compounds, saxagliptin and dapagliflozin. The companies will split global sales and revenue on both products. Release

Related Articles:
BMS unveils positive diabetes data. Report
AstraZeneca, BMS ink billion-dollar pact on diabetes drugs. Report

1. AstraZeneca and Bristol-Myers Squibb
Read more on

Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Intrepida Bio launched with $9.5 million from Sofinnova and Canaan Partners to develop anti-BAG3 antibodies for the treatment of cancer.